Showing results (21-30 of 150) with videos related to
Sort By:
Pageof 15
Bioorganic & Medicinal Chemistry|December 22, 2009
Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2Stephen Hilton, Sebastien Naud, John J Caldwell, et al.Journal of Natural Products|October 6, 2011
The 2,11-cyclized cembranoids: cladiellins, asbestinins, and briarellins (period 1998-2010)Amanda J Welford, Ian CollinsFuture Medicinal Chemistry|March 16, 2016
Recent findings and future directions for interpolar mitotic kinesin inhibitors in cancer therapyStephanie M Myers, Ian CollinsJournal of Chemical Biology|July 2, 2009
Measuring and interpreting the selectivity of protein kinase inhibitorsLynette A Smyth, Ian CollinsMolecules (Basel, Switzerland)|October 29, 2014
Diversity-oriented synthetic strategies applied to cancer chemical biology and drug discoveryIan Collins, Alan M JonesCancer Research|January 20, 2004
The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathwaySteven R Whittaker, Mike I Walton, Michelle D Garrett, et al.Journal of Medicinal Chemistry|March 19, 2008
Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaborationJohn J Caldwell, Thomas G Davies, Alastair Donald, et al.The FEBS Journal|May 16, 2008
Phosphorylation of cyclin dependent kinase 4 on tyrosine 17 is mediated by Src family kinasesNicholas G Martin, Peter C McAndrew, Paul D Eve, et al.Progress in Cell Cycle Research|November 5, 2003
The contemporary drug development process: advances and challenges in preclinical and clinical developmentMichelle D Garrett, Mike I Walton, Edward McDonald, et al.Drug Discovery Today. Technologies|June 16, 2019
A critical evaluation of the approaches to targeted protein degradation for drug discoveryRajesh Chopra, Amine Sadok, Ian CollinsPageof 15